DUPIXENT
dupilumabmAbIL-4Rα blocker
Atopic Dermatitis
Approved
1 program·1 trial·View drug →
DashboardSell16,897$128.71−$2.2MSell13,557$116.74−$1.6MBuy9,712$141.17+$1.4MSell15,020$107.89−$1.6MOption ex.23,722$134.36$3.2MBuy45,806$139.56+$6.4M Allergy & ImmunologyCo-Investigator$579.1K5RheumatologyResearch Grant$544.1K6RheumatologyCo-Investigator$544.1K6DermatologyEquity / Ownership$517.8K4Allergy & ImmunologyResearch Grant$376.5K5DermatologyCo-Investigator$341.6K3DermatologyResearch Grant$340.8K6Allergy & ImmunologyCo-Investigator$266.2K6RheumatologyEquity / Ownership$262.1K5DermatologyCo-Investigator$236.7K5
REGNNASDAQ
Regeneron
Regeneron Pharmaceuticals, Inc. · Tarrytown, NY · founded 1988
Regeneron Pharmaceuticals, based in Tarrytown, New York, is a biotechnology company built around proprietary platforms for discovering antibody and protein-trap drugs. Its largest commercial product is EYLEA for retinal diseases, and it co-markets DUPIXENT (atopic dermatitis, asthma, COPD) with Sanofi. The pipeline spans oncology bispecifics (Libtayo, Lynozyfic), rare disease, and a deep antibody-engineering platform.
- Lead asset
- DUPIXENT · Approved · Atopic Dermatitis
- mAb · IL-4Rα blocker
- Pipeline
- 1 drug · 1 program
- 1 Immunology
- Modalities
- mAb×1
FocusOncology - SolidImmunologyRare Disease
$745.00-6.73%1Y
REGN · daily close · illustrative · 3 catalysts marked
PDUFA-22%Conf.+9%PDUFA-47%
1Y high$811.861Y low$737.42range$74.44(10%)past catalysts
Peers in this space
Pipeline & catalysts
Pipeline & catalysts
Pipeline by phase1programs
- Preclin0
- Ph10
- Ph20
- Ph30
- Filed0
- Approved1
Past catalyst impact
DateKindEventOutcome+1W+1M+6M
Oct 27, 2025PDUFADUPIXENT — PDUFA — ApprovedMixed-21.7%+19.2%+25.1%
May 30, 2025Conf.DUPIXENT — ASH Late-Breaker — Updated SurvivalPositive+8.9%+9.4%+5.8%
Apr 30, 2025PDUFADUPIXENT — PDUFA — ApprovedNegative-46.5%-34.3%-46.9%
Oct 2, 2024PDUFADUPIXENT — PDUFA — ApprovedNegative-22.8%-46.5%-38.7%
% change vs ticker close on the announcement date · backtest illustrative
Smart money
Insider activity
Insider activity · last 90 days
Form 4 trail · 6 transactions · 5 insiders
Net flow
+$2.4M
Buys
$7.8M
2 txns
Sells
$5.4M
3 txns
Largest
+$6.4M
CFO buy
Net flow per quarter · last 8Q
8 txns · sum +$1.38M
24Q325Q125Q326Q126Q2
buys · $7.76Msells · $6.38M
Insider · roleActionSharesPriceValueDate
P. Mendoza
COO
Apr 25, 2026
M. Nguyen
CFO
Apr 16, 2026
C. O'Connor
CMO
Apr 7, 2026
D. Mendoza
COO
Apr 5, 2026
M. Nguyen
CFO
Apr 2, 2026
C. Lindberg
CFO
Feb 5, 2026
Congressional trading
Congressional trading · STOCK Act · last 365d
5 trades · 5 members
Est. net flow
+$1.67M
midpoint · brackets only
Buys
1
Sells
4
Party mix
1 D4 R
Member · chamberActionBracket~ midpointOwnerDate · disclosure
R
Sell$250K–$500K~$375KselfSen. B. Tucker
Senate · TN
Mar 20, 2026
filed +39d
R
Sell$100K–$250K~$175KselfRep. G. Ostrom
House · OH
Jan 13, 2026
filed +26d
D
Sell$500K–$1.00M~$750KspouseRep. L. Marquez
House · NM
Aug 3, 2025
filed +40d
R
Buy$1.00M–$5.00M~$3.00MselfRep. M. Hartwell
House · FL
Jul 19, 2025
filed +26d
R
Sell$15K–$50K~$33KselfRep. N. Schaefer
House · WI
May 27, 2025
filed +15d
Source: Senate eFD & House Clerk PTR feeds · members must disclose within 45 days · midpoints reflect bracket midpoint, not actual transaction value
Top ETF holders
ETF holders · NAV disclosures
5 ETFs hold the position
Held by ETFs
$138.4M
aggregate position
Of market cap
0.18%
aggregate ETF share
Top holder
VHT0.29%
Vanguard Health Care ETF
TickerETF · familyThemeNAV% of NAVPosition
VHTBroad healthcare$19.00B0.29%$55.1M
Vanguard Health Care ETF
Vanguard
XLVBroad healthcare$39.00B0.13%$50.7M
Health Care Select Sector SPDR
SPDR
IBBBroad biotech$8.40B0.17%$14.3M
iShares Biotechnology ETF
iShares
IYHBroad healthcare$3.40B0.33%$11.2M
iShares U.S. Healthcare ETF
iShares
XBIBroad biotech$7.90B0.09%$7.1M
SPDR S&P Biotech ETF
SPDR
Source: ETF NAV disclosures + quarterly 13F filings · narrow-theme ETFs disclose holdings daily; broad ETFs quarterly · % of NAV is the position weight inside the fund
KOL network
KOL network · CMS OpenPayments
30 physicians paid · 122 disclosed records
Total 2025+2024
$6.52M
YoY
+15%
Co-Investigator$2.42MResearch Grant$1.71MEquity / Ownership$1.63MConsulting$426.3KSpeaking$241.6KTravel & Lodging$86.3KFood & Beverage$3.1K
Physician · affiliationSpecialtyTop categoryTotalRecords
Dr. Theo Romano
Penn Medicine
Dr. James Chen
Vanderbilt
Dr. Ahmed Walsh
Memorial Sloan Kettering
Dr. Robert Lindberg
Cleveland Clinic
Dr. Theo Müller
NYU Langone
Dr. Theo Hoffman
University of Michigan
Dr. Theo Tanaka
NYU Langone
Dr. Vivian Davies
NYU Langone
Dr. Lin Lindberg
Cedars-Sinai
Dr. Vivian Reyes
Cedars-Sinai
Source: CMS OpenPayments · quarterly drops · physicians identified by NPI · aggregated across all programs
Government & IP
Federal lobbying
Federal lobbying · LDA · last 8 quarters
$1.79M disclosed · 2 firms engaged
YoY change
+8%
last 4Q vs prior 4Q
24Q3Q425Q1Q2Q3Q426Q1Q2
Top lobbying firms · last 8Q
Van Scoyoc Associates$1.24M
7 quarters active
Cornerstone Government Affairs$551K
4 quarters active
Top issues lobbied
- Prescription Drug User Fee programs$1.24M
- FDA user fee reauthorization (PDUFA / BsUFA)$184K
- BIOSIM Act / Biosimilars$184K
- Patent Trial and Appeal Board reforms$184K
Source: Senate LDA database (lda.senate.gov) · quarterly registrant filings · spend is the company-wide total disclosed
Government contracts
Federal contracts · USAspending.gov
6 awards · 4 agencies
Total awarded
$240.4M
across all programs
Active
$223.5M
option periods incl.
Top agency
HHS$176.7M
largest active: Strategic National Stockpile — Therapeutic Procurement
AgencyTitle · type · award IDStatusValueAwarded → ends
HHSactive$142.7MMar 2026→ Dec 2029
Strategic National Stockpile — Therapeutic Procurement
Contract · HHS-70755775
DoD / DHAactive$39.4MMar 2025→ Apr 2027
Battlefield Trauma Therapeutics R&D
Contract · DDD-30133432
VAcompleted$14.5MJan 2025→ Feb 2026
Veterans Health Administration — Specialty Drug Supply
Contract · VA-09045538
NIH / NICHDcompleted$2.4MJun 2024→ Oct 2025
Pediatric Rare Disease Natural History Study
Grant · NIH-78118198
HHSactive$33.9MNov 2023→ Aug 2027
Strategic National Stockpile — Therapeutic Procurement
Contract · HHS-30230614
DoD / DHAactive$7.3MOct 2023→ Jun 2027
Battlefield Trauma Therapeutics R&D
Contract · DDD-04298711
Source: USAspending.gov · SAM.gov · every federal contract / grant / cooperative agreement is public · values are obligated awards (may include option periods)
U.S. Patents
U.S. Patents · USPTO
5 granted · 4 pending
Total in portfolio
9
Granted in last 12mo
0
Expiring < 2yr
0
Nearest expiry
Apr 2031
Patent #Title · inventor · drugTypeStatus · filedExpiry
US 2026/0227990 A1Composition of Matter
Therapeutic peptide compositions for DUPIXENT
A. Kowalski + 1 · DUPIXENT
pendingfiled Apr 2026
in prosecution
US 2023/6268755 A1Process
Purification methods for DUPIXENT
K. Goldstein + 4 · DUPIXENT
pendingfiled Apr 2023
in prosecution
11,760,470Process
Recombinant production of therapeutic DUPIXENT
D. Kim · DUPIXENT
grantedfiled Apr 2019
exp. Apr 2039
13.0y left
10,261,804Composition of Matter
Bispecific antibody compositions targeting DUPIXENT
J. Hoffman · DUPIXENT
grantedfiled Apr 2017
exp. Apr 2037
11.0y left
US 2019/6023210 A1Device
Drug delivery device for autoinjection of DUPIXENT
C. Nguyen · DUPIXENT
pendingfiled Apr 2019
in prosecution
10,771,390Method of Use
Combination therapy comprising DUPIXENT
A. Walsh + 1 · DUPIXENT
grantedfiled Apr 2015
exp. Apr 2035
9.0y left
10,087,036Composition of Matter
Modified RNA constructs and methods of use thereof DUPIXENT
P. Davies + 4 · DUPIXENT
grantedfiled Apr 2012
exp. Apr 2032
6.0y left
10,934,663Device
Gene therapy delivery system for DUPIXENT
L. Walsh + 2 · DUPIXENT
grantedfiled Apr 2011
exp. Apr 2031
5.0y left
showing 8 of 9 · full portfolio available on Pro
Source: USPTO PEDS & Patent Public Search · composition-of-matter is the headline asset · expiration = 20 years from filing
News
News
News · last 90 days
13 items from 5 categories
clinical7regulatory3analyst1earnings1corporate1
3d ago
REGN reports topline results from Phase 2 trial of DUPIXENT
Endpoints News$·clinical
8d ago
REGN presents DUPIXENT data at major medical conference
FierceBiotech·clinical
11d ago
Analyst initiates coverage of REGN with Buy rating
Reuters·analyst
12d ago
REGN reports Q1 financial results and pipeline update
Business Wire·earnings
20d ago
EMA validates REGN's Marketing Authorization Application for DUPIXENT
Endpoints News$·regulatory
22d ago
REGN completes enrollment in DUPIXENT Phase 2 trial
Endpoints News$·clinical
1mo ago
FDA accepts REGN's NDA for DUPIXENT; PDUFA date set
Endpoints News$·regulatory
1mo ago
REGN announces interim analysis from DUPIXENT pivotal study
FierceBiotech·clinical
1mo ago
REGN reports topline results from Phase 2 trial of DUPIXENT
FierceBiotech·clinical
2mo ago
REGN presents DUPIXENT data at major medical conference
FierceBiotech·clinical
2mo ago
REGN provides corporate update at investor conference
Business Wire·corporate
2mo ago
REGN doses first patient in Phase 3 DUPIXENT study
FierceBiotech·clinical
3mo ago
FDA grants Fast Track Designation to REGN's DUPIXENT program
Endpoints News$·regulatory
Sources: PR wires + biotech-trade publications + company IR · paywalled outlets ($) link to publisher · we never paraphrase the headline
Financials
Financials
Trading
Previous close
$745.00
Open
$746.49
Day Δ
-1.49
-0.20%
Day range
$739.78 – $751.72
52W range
$737.42 – $811.86
Avg daily volume
510K
Valuation & ownership
Enterprise value
$67.5B
Shares out
102.01M
Float
92.83M
Insider %
4.50%
Institutional %
54.50%
Beta
1.00
vs SPY · 52w
Balance sheet & burn
Cash + invest
$16.3B
Total debt
$3.8B
Debt / equity
2.50
Cash burn / Q
$143M
R&D spend TTM
$501M
3% of cash
ATM available
$11.4B
dilution risk
Earnings
EPS latest
$-0.05
EPS Δ vs prior
+0.10
EPS estimate
$-0.15
next quarter
EPS prior
$-0.15
Next earnings
May 3, 2026
Rev guidance
$380M